Seattle Genetics (SGEN) Tops Q3 EPS by 8c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
BofA/Merrill Lynch Upgrades Seattle Genetics (SGEN) to Neutral
October 27, 2017 6:15 AM EDTBofA/Merrill Lynch upgraded Seattle Genetics (NASDAQ: SGEN) from Underperform to Neutral with a price target of $70.00 (from $55.00).
Analyst Tazeen Ahmad believes the Adcetris product will be more positive in the LT and remains constructive on uptake.
For an analyst ratings... More
